— Fundamental Stock Analysis and Report Card
Located in New Brunswick, NJ, US. Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q2 2026 Total ($) | Q2 2026 Margin (%) | |
|---|---|---|
| Revenue | 25.3b +1.6b +6.6% | |
| Gross Income | 18.5b +2.4b +14.8% | 73% +5.2pp +7.7% |
| EBITDA | 7.2b -1.6b -17.9% | 28% -8.5pp -23.0% |
| Operating Income | 7.2b +364.0m +5.3% | 28% -0.3pp -1.2% |
| Net Income | 5.5b -3.0m -0.1% | 22% -1.5pp -6.2% |
| Earnings Per Share | 2.27 +0.0 -0.9% | |
| Operating Cash Flow | 2.5b -1.7b -39.8% | 10% -7.6pp -43.5% |
| Free Cash Flow | 1.5b -1.9b -56.6% | 6% -8.4pp -59.3% |
| Research & Development | 3.7b +137.0m +3.9% | 14% -0.4pp -2.5% |
What are the analysts saying?
Analyst Consensus aggregates Wall Street recommendations into buy/hold/sell counts, while the Fundamental Scorecard grades the company on six financial ratios (P/B, P/E, D/E, ROA, ROE, DCF) plus an overall score. The two measure different things and can point in different directions.